US 12,673,085 B2Grant
CBM uses
Issue Date:2026-07-07
•9 Claims
•16 Drawing Sheets
Abstract
The present disclosure provides molecules which modulate cell growth. These molecules include those that bind carbohydrates and may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.
Metadata
Assignee
- OMIDEON LIMITED
Inventors
- Graeme Rogers
- Helen Connaris
Application Information
Application Number:US 17/425,374
Filing Date:2020-01-24
Priority Date:2019-01-25
Art Unit:1642
Classifications
IPC:
A61K38/16A61P35/00
Field of Search:
A61K 38/164A61K 38/43A61P 35/00
Patent Drawings (16 sheets)
Description
Related Applications
[0001] This application is a 35 U.S.C. § 371 national stage of PCT Application No. PCT/GB2020/050170, filed on Jan. 24, 2020, which claims priority from United Kingdom Patent Application No. 1901057.8, filed on Jan. 25, 2019, the contents of which are incorporated herein by reference. The above-referenced PCT International Application was published in the English language as International Publication No. WO 2020/152479 A1 on Jul. 30, 2020.
Statement Regarding Electronic Filing of a Sequence Listing
[0002] A Sequence Listing in ASCII text format, submitted under 37 C.F.R. § 1.821, entitled 9013-196_ST25.txt, 81,963 bytes in size, generated on Aug. 3, 2021 and filed via EFS-Web, is provided in lieu of a paper copy. This Sequence Listing is incorporated by reference into the specification for its disclosures.
Field of the Invention
[0003] The present invention provides uses, methods and compositions for the treatment of cancer.
Background of the Invention
[0004] Some lectins, which are glycoproteins of non-immune origin, exhibit an ability to induce apoptosis in malignant cells and thus demonstrate anti-cancer properties. This phenomenon occurs, in part, through the interaction of these lectins with specific glycan receptors on immune cells (Yau et al., 2015).
[0005] One such lectin is Viscumin from mistletoe, which is a toxin that binds to cellular receptors that are glycosylated with α2,6 sialyllactose (Muthing et al., 2002). Viscumin is a 57 kDa heterodimer, comprising of two subunits A and B. The A subunit exerts its toxic effect by disabling ribosomes, thereby interrupting protein production, whereas the B subunit exhibits glycan binding function. The lectin demonstrates picomolar cytotoxicity in vitro and in vivo, and has a recommended dose upper limit of 6 μg/kg in clinical trial subjects (half-life of 13 mins) (Zwierzina et al., 2011).
[0006] Another plant lectin that has demonstrated an ability to prevent cell migration and growth (and hence an anti-cancer property) is the Maackia amurensis seed lectin, or MASL (Ochoa-Alvarez et al., 2012; Astarita et al., 2012). This lectin is also cytotoxic exhibiting nanomolar potency (~300 nM), and exerts its effects through the binding of podoplanin, an α2,3 sialylated mucin-type transmembrane glycoprotein, that is overexpressed in a variety of human cancers (Kato et al., 2005; Schacht et al., 2005; Shibahara et al., 2006).
[0007] WO2018/055373 describes the use of sialic acid binding molecules, including carbohydrate binding modules, in methods of modulating cell growth and in the treatment and/or prevention of cell proliferation and/or differentiation disorders.
[0008] The treatment of cell proliferation and differentiation disorders, including, for example cancer, demands the provision of additional molecules that are well tolerated in their hosts and have therapeutic potential.
Summary of the Invention
[0009] The present disclosure is based on the finding that a class of sugar (carbohydrate)-binding proteins known as carbohydrate-binding modules (CBMs) may modulate aspects of cell growth and/or cell activity.
[0010] Accordingly, the disclosure provides various uses, including medical uses of molecules comprising the CBMs described herein.
[0011] CBMs are often found as part of a larger enzyme (for example, a carbohydrate-active enzyme such as a glycosidase) where their role is to bind a carbohydrate ligand and direct the catalytic domain of the enzyme towards its substrate.
[0012] The disclosure specifically concerns those CBMs which belong to the groups known as
-
- [0013] (i) carbohydrate binding module Family 32 (CBM32);
- [0014] (ii) carbohydrate binding module Family 47 (CBM47)
- [0015] (iii) carbohydrate binding module Family 67 (CBM67)
- [0016] (iv) carbohydrate binding module Family 70 (CBM70)
[0017] In this regard, the disclosure relates to the finding that CBMs from all of the CBM families described above (CBM families (i)-(iv)) modulate aspects of cell growth and/or cell activity.
[0018] The terms “CBM32”, “CBM47”, “CBM67” and “CBM70” as used herein may refer to compounds, compositions or molecules which comprise one or more carbohydrate binding module(s) and which are classed as belonging to the carbohydrate binding module families 32, 47, 67 and/or 70. The term “CBM32” as used herein may embrace and/or encompass those carbohydrate binding modules designated as belonging to the CBM32 family in the Carbohydrate Active Enzymes database (freely accessible on the internet). Additionally, the terms “CBM47”, “CBM67” and “CBM70” as used herein may embrace and/or encompass those carbohydrate binding modules designated as belonging to the CBM47, CBM67 and CBM70 families in the Carbohydrate Active Enzymes database (freely accessible on the internet).
[0019] The disclosure may embrace the use of molecules, for example, larger molecules, which comprise a CBM, for example, a CBM32, a CBM47, a CBM67 and a CBM70. By way of (non-limiting) example, the molecules of this disclosure may not only exhibit an ability to bind sialic acid but may also have one or more other functions. For example, the molecules may have enzymatic activity.
[0020] In some instances, the CBM for the various uses described herein, may not be provided as part of, or comprised within, a molecule (for example a fusion protein) with enzymatic (for example, sialidase) activity.
[0021] It should be noted that throughout this specification, the terms “comprise”, “comprising” and/or “comprises” is/are used to denote that aspects and embodiments of this invention “comprise” a particular feature or features. It should be understood that this/these terms may also encompass aspects and/or embodiments which “consist essentially of” or “consist of” the relevant feature or features.
[0022] As such, within the context of this disclosure a “CBM32”, “CBM47”, “CBM67” and/or “CBM70” may comprise, consist essentially of or consist of, one or more molecules classed as belonging to the carbohydrate binding module families 32, 47, 67 and/or 70. The terms “CBM32”, “CBM47”, “CBM67” and/or “CBM70” may embrace fragments or portions of native, wild type or reference CBM32s, CBM47s, CBM67s and/or CBM70s—any such fragments or portions should be functional, that is to say, they retain the carbohydrate binding ability of a native, wild type or reference CBM32, CBM47, CBM67 and/or CBM70 from which they are derived.
[0023] Useful CBM32s may be derived from any suitable source. For example, CBM32s for use may be obtained from microorganisms, including, for example, bacteria of the genera Cellvibrio, Yersinia, Micromonospora, Streptococcus, Bifidobacteria and Clostridium. For example, useful CBM32s may be obtained or derived from, for example, Cellvibrio mixtus, Yersinia enterolitica, Clostridium perfringens, Clostridium thermocellum, Streptococcus pneumoniae, Bifidobacterium longum and Micromonospora viridifaciens. Further details concerning the source, structure and function of the CBM32 family can be found within the Carbohydrate Active Enzymes database (freely available on the internet).
[0024] An exemplary CBM32 sequence is provided by SEQ ID NO: 1 below:
[0025]
| SEQ ID NO: 1 | |
| AIIETAIPQSEMTASATSEEGQDPASSAIDGNTNTMW | |
| HTKWNGSDALPQSLSVNLGSSRKVSSIAITPRTSGNN | |
| GFITKYEIHAINNGVETLVAEGTWEENNLVKTVTFDS | |
| PIDAEEIKITAIQGVGGFASIAELNVYE |
[0026] Accordingly, a CBM for use may comprise, consist essentially or consist of a CBM having the sequence of SEQ ID NO: 1 or a carbohydrate binding portion thereof.
[0027] A carbohydrate binding fragment of SEQ ID NO: 1 may comprise anywhere between about 5, 6, 7, 8, 9 or 10 (consecutive or contiguous) amino acids to about 138 (consecutive or contiguous) amino acids from SEQ ID NO: 1. Suitable fragments may comprise about 11, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130 or about 135 (consecutive or contiguous) amino acids from SEQ ID NO: 1.
[0028] CBM32 or a protein comprising, consisting essentially or consisting of SEQ ID NO: 1 may bind, for example, galactose, N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and/or lactose. Accordingly, any fragment for use may also bind galactose, N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and/or lactose. One of skill will appreciate that the binding affinity of any given CBM32 molecule may depend on the precise CBM32 subtype; by way of further examples, some CBM32s have shown affinity for a variety of ligands (examples include type II blood group H-trisaccharide (Fuca1-2Galb1-4GlcNAc), N-acetyl-D-lactosamine (LacNAc), galactose, lacto-N-biose, disaccharide GlcNAc-α-1,4-Gal (which may be referred to as an N-acetylglucosamine linked alpha 1,4 to galactose), and/or GlcNAc). It should also be noted that multiple CBM32 subtypes may be derived from a single organism; these different CBM subtypes may exhibit the same, similar or different binding specificities. For example, Clostridium perfringens contains two sialidases NanJ and NanH; NanJ contains one galactose-specific CBM32; NanH contains four putative CBM32s with different binding selectivity—for example, the CBM32 encoded by NanH binds GlcNAc. As used herein, the term CBM32 embraces all CBM32 variants, derivatives and sub-types.
[0029] SEQ ID NO: 1 is derived from the sequence deposited in the UniProt database under ID No: A0A2X2YJF2. This sequence is reproduced as SEQ ID NO: 2 below (SEQ ID NO: 1 appears as residues 42-180—shown in bold in the sequence below):
[0030]
| SEQ ID NO: 2 | |
| MKSKKIIATL VASLVISNMG GYLVKANPNV | |
| NHKAVIIEDR QAIIETAIPQ SEMTASATSE | |
| EGQDPASSAI DGNTNTMWHT KWNGSDALPQ | |
| SLSVNLGSSR KVSSIAITPR TSGNNGFITK | |
| YEIHAINNGV ETLVAEGTWE ENNLVKTVTF | |
| DSPIDAEEIK ITAIQGVGGF ASIAELNVYE | |
| IKGEVDEIAN YGNLKITKEE ERLNITRDLE | |
| KFSSLDEGTI VTRFNMNDTS IQSLIGLSDG | |
| NKANNYFSLY VSGGKVGYEL RRQEGNGDFN | |
| VHHSADVTFN KGINTLALKI EKGVGAKIFL | |
| NGSLVKTVSD PNIKFLNAIN LNSGFIGKTD | |
| RANGYNEYLF RGNIDFMNIY DKPVSDNYLL | |
| RKTGETKAPS EDSLLPDDVY KTQPVELFYP | |
| GYLESRGYRI PALETTKKGT VLASIDVRNN | |
| GDHDAPNNNI DVGIRRKEVN GEWEEGKVIL | |
| DYPGKSAAID TSLMSATIEE NGIEKERIFL | |
| IVTHFPEGYG FPNTEGGSGY KEIDGKYYFI | |
| LKDAQNNEYT VREDGIVYNS EGNETDYVMK | |
| NDKTLIQNGE EVGNALLSNS PLKAVGTAHI | |
| EMIYSDDDGN TWSEPEDLNP GLKKEWMKFF | |
| GTAPGKGIQI KNGEHKGRLV FPIYYTNQNN | |
| FQSSAVIYSD DFGETWKLGE SPIDTASVSS | |
| ETVSSGTQLT ECQVVEMPNG QLKLFMRNTG | |
| SYTRIATSFD GGATWHDEVP EDTSLREPYC | |
| QLSVINYSGK INGKDAIIFS NPDASSRVNG | |
| SVKVGLINEN GTYENGQPRY EFDWIYNKTV | |
| KPGSFAYSCL TELPDGNLGL FYEGEGAGRM | |
| AYTEFDLNYL KFNASEDSPA ATVQSIESLD | |
| EDLIYNAGDE VSIKVNFNQL VSLIGDRKIT | |
| LDIGGVDVPL NMVNYEGKSS AIFKGTIPEG | |
| INPGNYEIKL KENNALELNT VYNKVSTLNG | |
| LDNTGINVQI GELKTTVGNS TIKVNEEVQV | |
| GSAFEAILGI KGLNGDTEVY SAEYLFEYNA | |
| EAFKLNEITS FSDSLFVKSK EVEPGKVRIL | |
| VASLGNEIEK DSELVKVNLT PKISSELEVL | |
| GLTTALVGAG DGNTHDLELS SKEVKINEEA | |
| SGEIVVNPVQ NFEIPEINKK NVKLTWNAPI | |
| TTEGLEGYVI YKDGKKLSEV PAESTEFVVS | |
| KLNRHTIYNF KVAAKYSNGE LSAKESKTIR | |
| TAR |
[0031] SEQ ID NOS 1 and 2 are derived from Clostridium perfringens.
[0032] A CBM for use in the various aspects of this disclosure may comprise one, two, three, four or more CBM32s.
[0033] A CBM for use may comprise one, two, three, four or more proteins comprising SEQ ID NO: 1 or a carbohydrate binding fragment thereof.
[0034] One of skill will appreciate that useful CBM32s may comprise sequences which exhibit some degree (for example, 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%) of sequence identity or homology with the CBM32 sequences of SEQ ID NOS: 1 and 2. All such variant or divergent sequences are to be embraced within the scope of this disclosure and by the term “CBM32”. Identical and/or homologous CBM32 sequences may have carbohydrate binding function.
[0035] CBM47s may be derived from any suitable source. For example, CBM47s for use may be obtained from microorganisms, including, for example, bacteria of the genera Acinetobacter, Bathymodiolus, Campylobacter, Planctomycetes, Streptococcus and Streptomyces. For example, useful CBM47s may be obtained or derived from, for example, Streptococcus mitis or Streptococcus pneumoniae. Further details concerning potential sources and the structure and function of the CBM47 family can be found within the Carbohydrate Active Enzymes database (freely available on the internet).
[0036] An exemplary CBM47 sequence is provided by SEQ ID NO: 3 below:
[0037]
| SEQ ID NO: 3 | |
| TPDKFNDGNLNIAYAKPTTQSSVDYNGDPNRAVDGNR | |
| NGNFNSGSVTHTRADNPSWWEVDLKKMDKVGLVKIYN | |
| RTDAETQRLSNFDVILYDNNRNEVAKKHVNNLSGESV | |
| SLDFKEKGARYIKVKLLTSGVPLSLAEVEVFRES |
[0038] Accordingly, a CBM for use may comprise, consist essentially or consist of a CBM having the sequence of SEQ ID NO: 3 or a carbohydrate binding portion thereof.
[0039] A carbohydrate binding fragment of SEQ ID NO: 3 may comprise anywhere between about 5, 6, 7, 8, 9 or 10 (consecutive or contiguous) amino acids to about 144 (consecutive or contiguous) amino acids from SEQ ID NO: 3. Suitable fragments may comprise about 11, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130 or about 135, about 140 or about 143 (consecutive or contiguous) amino acids from SEQ ID NO: 3.
[0040] CBM47 or a protein comprising, consisting essentially or consisting of SEQ ID NO: 3 may bind L-fucose, fucosyllactose, H-trisaccharide and/or Lewisy antigen. Accordingly, any fragment for use may also bind L-fucose, fucosyllactose, H-trisaccharide and/or Lewisy antigen.
[0041] SEQ ID NO: 3 is derived from the sequence deposited in the UniProt database under ID No: A0A1Q2T229. This sequence is reproduced as SEQ ID NO: 4 below (SEQ ID NO: 3 appears as residues 601-745—shown in bold in the sequence below):
[0042]
| SEQ ID NO: 4 | |
| MNKEKIKRKL ITILFVCIGM LCFGLLAGVK | |
| ADNRVQMRTT INNESPLLLS PLYGNDNGNG | |
| LWWGNTLKGA WEAIPEDVKP YAAIELHPAK | |
| VCKPTSCIPR DTKELREWYV KMLEEAQSLN | |
| IPVFLVIMSA GERNTVPPEW LDEQFQKYSV | |
| LKGVLNIENY WIYNNQLAPH SAKYLEVCAK | |
| YGAHFIWHDH EKWFWETIMN DPTFFEASQK | |
| YHKNLVLATK NTPIRDDAGT DSIVSGFWLS | |
| GLCDNWGSST DTWKWWEKHY TNTFETGRAR | |
| DMRSYASEPE SMIAMEMMNV YTGGGTVYNF | |
| ECAAYTFMTN DVPTPAFTKG IIPFFRHAIQ | |
| NPAPSKEEVV NRTKAVFWNG EGRISSLNGF | |
| YQGLYSNDET MPLYNNGRYH ILPVIHEKID | |
| KEKISSIFPN AKILTKNSEE LSSKVNYLNS | |
| LYPKLYEGDG YAQRVGNSWY IYNSNANINK | |
| NQQVMLPMYT NNTKSLSLDL TPHTYAVVKE | |
| NPNNLHILLN NYRTDKTAMW ALSGNFDASK | |
| SWKKEELELA NWISKNYSIN PVDNDFRTTT | |
| LTLKGHTGHK PQINISGDKN HYTYTENWDE | |
| NTHVYTITVN HNGMVEMSIN TEGTGPVSFP | |
| TPDKFNDGNL NIAYAKPTTQ SSVDYNGDPN | |
| RAVDGNRNGN FNSGSVTHTR ADNPSWWEVD | |
| LKKMDKVGLV KIYNRTDAET QRLSNFDVIL | |
| YDNNRNEVAK KHVNNLSGES VSLDFKEKGA | |
| RYIKVKLLTS GVPLSLAEVE VFRESDGKQS | |
| EEDIDKITED KVVSTNKVAT QSSTNYEGVA | |
| ALAVDGNKDG DYGHHSVTHT KEDSPSWWEI | |
| DLAQTEELEK LIIYNRTDAE IQRLSNFDII | |
| IYDSNDYEVF TQHIDSLESN NLSIDLKGLK | |
| GKKVRISLRN AGIPLSLAEV EVYTYK |
[0043] SEQ ID NOS 3 and 4 are derived from Streptococcus pneumoniae.
[0044] A CBM for use in the various aspects of this disclosure may comprise one, two, three, four or more CBM47s.
[0045] A CBM for use may comprise one, two, three, four or more proteins comprising SEQ ID NO: 3 or a carbohydrate binding fragment thereof.
[0046] One of skill will appreciate that useful CBM47s may comprise sequences which exhibit some degree (for example, 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%) of sequence identity or homology with the CBM47 Sequences of SEQ ID NOS: 3 and 4. All such variant or divergent sequences are to be embraced within the scope of this disclosure and by the term “CBM47”. Identical and/or homologous CBM47 sequences may have carbohydrate binding function.
[0047] CBM67s may be derived from any suitable source. For example, CBM67s for use may be obtained from microorganisms, including, for example, bacteria of the genera Bacillus, Paenibacillus, Planctomycetes and Streptomyces. For example, a useful CBM67s may be obtained or derived from, for example, Streptomyces avermitilis. Further details concerning potential sources and the structure and function of the CBM67 family can be found within the Carbohydrate Active Enzymes database (freely available on the internet).
[0048] An exemplary CBM67 sequence is provided by SEQ ID NO: 5 below:
[0049]
| SEQ ID NO: 5 | |
| APSLEGSSWIWFPEGEPANSAPAATRWFRRTVDLPD | |
| DITGATLAISADNVYAVSVDGAEVARTDLEADNEGW | |
| RRPAVIDVLDHVHSGNNTLAVSASNASVGPAGWICV | |
| LVLTTASGEKKIFSDASWKSTDHEPADGWREPDFDD | |
| SGWPAAKVAAAWGAGPWGRVA |
[0050] Accordingly, a CBM for use may comprise, consist essentially or consist of a CBM having the sequence of SEQ ID NO: 5 or a carbohydrate binding portion thereof.
[0051] A carbohydrate binding fragment of SEQ ID NO: 5 may comprise anywhere between about 5, 6, 7, 8, 9 or 10 (consecutive or contiguous) amino acids to about 164 (consecutive or contiguous) amino acids from SEQ ID NO: 5. Suitable fragments may comprise about 11, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135 about 140, about 145, about 150, about 155, about 160 or about 163 (consecutive or contiguous) amino acids from SEQ ID NO: 5.
[0052] CBM67 or a protein comprising, consisting essentially or consisting of SEQ ID NO: 5 may bind L-rhamnose. Accordingly, any fragment for use may also bind L-rhamnose.
[0053] SEQ ID NO: 5 is derived from the sequence deposited in the UniProt database under ID No: Q82PP4. This sequence is reproduced as SEQ ID NO: 6 below (SEQ ID NO: 5 appears as residues 132-296—shown in bold in the sequence below):
[0054]
| SEQ ID NO: 6 | |
| MSALRVTSPS VEYVQRPLGL DAAHPRLSWP | |
| MASAAPGRRQ SAYQVRVASS AAGLSHPDVW | |
| DSGKVVSDDS VLVPYAGPPL KPRTRYFWSV | |
| RVWDADGGAS EWSAPSWWET GLMGASQWSA | |
| KWISAPAPLT EAPSLEGSSW IWFPEGEPAN | |
| SAPAATRWFR RTVDLPDDIT GATLAISADN | |
| VYAVSVDGAE VARTDLEADN EGWRRPAVID | |
| VLDHVHSGNN TLAVSASNAS VGPAGWICVL | |
| VLTTASGEKK IFSDASWKST DHEPADGWRE | |
| PDFDDSGWPA AKVAAAWGAG PWGRVAPVAS | |
| AANQLRHEFR LPHKKVSRAR LYATALGLYE | |
| AHLNGRRVGR DQLAPGWTDY RKRVQYQTYD | |
| VTSSVRPGAN ALAAYVAPGW YAGNVGMFGP | |
| HQYGERPALL AQLEVEYADG TSERITSGPD | |
| WRAASGPIVS ADLLSGETYD ARKETAGWTS | |
| PGFDDRAWLA VRGADNDVPE QIVAQVDGPV | |
| RIAKELPARK VTEPKPGVFV LDLGQNMVGS | |
| VRLRVSGDAG TTVRLRHAEV LNPDGTIYTA | |
| NLRSAAATDT YTLKGQGEET YEPRFTFHGF | |
| RYVEVTGFPG KPSTTSVTGR VMHTSAPFTF | |
| EFETNVPMLN KLHSNITWGQ RGNFLSVPTD | |
| TPARDERLGW TGDINVFAPT AAYTMESARF | |
| LTKWLVDLRD AQTSDGAFTD VAPAVGNLGN | |
| GVAGWGDAGV TVPWALYQAY GDRQVLADAL | |
| PSVHAWLRYL EKHSDGLLRP ADGYGDWLNV | |
| SDETPKDVIA TAYFAHSADL AARMATELGK | |
| DAAPYTDLFT RIRKAFQTAY VASDGKVKGD | |
| TQSAYVLTLS MNLVPDALRK AAADRLVALI | |
| EAKDWHLSTG FLGTPRLLPV LTDTGHTDVA | |
| YRLLHQRTFP SWGYPIDKGS TTMWERWDSI | |
| QPDGGFQTPE MNSFNHYAYG SVGEWMYANI | |
| AGIAPGRAGY RQVVIRPRPG GEVTSARATF | |
| ASLHGPVSTR WQQRSGGFVL TCSVPPNTTA | |
| EVWIPADHPD RVQHTHGTFV RAEDGCAVFE | |
| VGSGSHRFTV |
[0055] SEQ ID NOS 5 and 6 are derived from Streptomyces avermitilis.
[0056] A CBM for use in the various aspects of this disclosure may comprise one, two, three, four or more CBM67s.
[0057] A CBM for use may comprise one, two, three, four or more proteins comprising SEQ ID NO: 5 or a carbohydrate binding fragment thereof.
[0058] One of skill will appreciate that useful CBM67s may comprise sequences which exhibit some degree (for example 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%) of sequence identity or homology with the CBM67 Sequences of SEQ ID NOS: 5 and 6. All such variant or divergent sequences are to be embraced within the scope of this disclosure and by the term “CBM67”. Identical and/or homologous CBM67 sequences may have carbohydrate binding function.
[0059] CBM70s may be derived from any suitable source. For example, CBM70s for use may be obtained from microorganisms, including, for example, bacteria of the genera Bacillus, Paenibacillus, Planctomycetes and Streptococcus. For example, a useful CBM70s may be obtained or derived from, for example, Streptomyces pneumoniae. Further details concerning potential sources and the structure and function of the CBM70 family can be found within the Carbohydrate Active Enzymes database (freely available on the internet).
[0060] An exemplary CBM70 sequence is provided by SEQ ID NO: 7 below:
[0061]
| SEQ ID NO: 7 | |
| NLVENGDFGQTEDGSSPWTGSKAQGWSAWVDQKNSA | |
| DASTRVIEAKDGAITISSHEKLRAALHRMVPIEAKK | |
| KYKLRFKIKTDNKIGIAKVRIIEESGKDKRLWNSAT | |
| TSGTKDWQTIEADYSPTLDVDKIKLELFYETGTGTV | |
| SFKDIELVEVADQLS |
[0062] Accordingly, a CBM for use may comprise, consist essentially or consist of a CBM having the sequence of SEQ ID NO: 7 or a carbohydrate binding portion thereof.
[0063] A carbohydrate binding fragment of SEQ ID NO: 7 may comprise anywhere between about 5, 6, 7, 8, 9 or 10 (consecutive or contiguous) amino acids to about 158 (consecutive or contiguous) amino acids from SEQ ID NO: 7. Suitable fragments may comprise about 11, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155 or about 157 (consecutive or contiguous) amino acids from SEQ ID NO: 7.
[0064] CBM70 or a protein comprising, consisting essentially or consisting of SEQ ID NO: 7 may bind hyaluronan. Accordingly, any fragment for use may also bind hyaluronan.
[0065] SEQ ID NO: 7 is derived from the sequence deposited in the UniProt database under ID No: Q54873. This sequence is reproduced as SEQ ID NO: 8 below (SEQ ID NO: 7 appears as residues 54-212—shown in bold in the sequence below):
[0066]
| SEQ ID NO: 8 | |
| MQTKTKKLIV SLSSLVLSGF LLNHYMTIGA | |
| EETTTNTIQQ SQKEVQYQQR DTKNLVENGD | |
| FGQTEDGSSP WTGSKAQGWS AWVDQKNSAD | |
| ASTRVIEAKD GAITISSHEK LRAALHRMVP | |
| IEAKKKYKLR FKIKTDNKIG IAKVRIIEES | |
| GKDKRLWNSA TTSGTKDWQT IEADYSPTLD | |
| VDKIKLELFY ETGTGTVSFK DIELVEVADQ | |
| LSEDSQTDKQ LEEKIDLPIG KKHVFSLADY | |
| TYKVENPDVA SVKNGILEPL KEGTTNVIVS | |
| KDGKEVKKIP LKILASVKDA YTDRLDDWNG | |
| IIAGNQYYDS KNEQMAKLNQ ELEGKVADSL | |
| SSISSQADRT YLWEKFSNYK TSANLTATYR | |
| KLEEMAKQVT NPSSRYYQDE TVVRTVRDSM | |
| EWMHKHVYNS EKSIVGNWWD YEIGTPRAIN | |
| NTLSLMKEYF SDEEIKKYTD VIEKFVPDPE | |
| HFRKTTDNPF KALGGNLVDM GRVKVIAGLL | |
| RKDDQEISST IRSIEQVFKL VDQGEGFYQD | |
| GSYIDHTNVA YTGAYGNVLI DGLSQLLPVI | |
| QKTKNPIDKD KMQTMYHWID KSFAPLLVNG | |
| ELMDMSRGRS ISRANSEGHV AAVEVLRGIH | |
| RIADMSEGET KQCLQSLVKT IVQSDSYYDV | |
| FKNLKTYKDI SLMQSLLSDA GVASVPRPSY | |
| LSAFNKMDKT AMYNAEKGFG FGLSLFSSRT | |
| LNYEHMNKEN KRGWYTSDGM FYLYNGDLSH | |
| YSDGYWPTVN PYKMPGTTET DAKRADSDTG | |
| KVLPSAFVGT SKLDDANATA TMDFTNWNQT | |
| LTAHKSWFML KDKIAFLGSN IQNTSTDTAA | |
| TTIDQRKLES GNPYKVYVND KEASLTEQEK | |
| DYPETQSVFL ESFDSKKNIG YFFFKKSSIS | |
| MSKALQKGAW KDINEGQSDK EVENEFLTIS | |
| QAHKQNRDSY GYMLIPNVDR ATFNQMIKEL | |
| ESSLIENNET LQSVYDAKQG VWGIVKYDDS | |
| VSTISNQFQV LKRGVYTIRK EGDEYKIAYY | |
| NPETQESAPD QEVFKKLEQA AQPQVQNSKE | |
| KEKSEEEKNH SDQKNLPQTG EGQSILASLG | |
| FLLLGAFYLF RRGKNN |
[0067] SEQ ID NOS 7 and 8 are derived from Streptococcus pneumoniae.
[0068] A CBM for use in the various aspects of this disclosure may comprise one, two, three, four or more CBM70s.
[0069] A CBM for use may comprise one, two, three, four or more proteins comprising SEQ ID NO: 7 or a carbohydrate binding fragment thereof.
[0070] One of skill will appreciate that useful CBM70s may comprise sequences which exhibit some degree (for example 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%) of sequence identity or homology with the CBM70 Sequences of SEQ ID NOS: 7 and 8. All such variant or divergent sequences are to be embraced within the scope of this disclosure and by the term “CBM70”. Identical and/or homologous CBM70 sequences may have carbohydrate binding function.
[0071] To summarise, a molecule for use in the various aspects and embodiments of this disclosure may comprise one or more CBM(s), for example, one or more CBM32(s), one or more CBM47(s), one or more CBM67(s) and/or one or more CBM70(s).
[0072] Molecules for use may comprise a single CBM selected from the group consisting of:
-
- [0073] a single CBM32;
- [0074] a single CBM47;
- [0075] a single CBM67; and
- [0076] a single CBM70.
[0077] Molecules for use may comprise a single CBM selected from the group consisting of:
-
- [0078] a single CpCBM32;
- [0079] a single SpCBM47;
- [0080] a single SaCBM67; and
- [0081] a single SpCBM70.
[0082] Where “Cp” means Clostridium perfringens—thus “CpCBM32” denotes that the CBM32 moiety is derived from Clostridium perfringens; “Sp” means Streptococcus pneumoniae—thus “SpCBM47” and “SpCBM70” denotes that the CBM47 and/or CBM70 moieties are derived from Streptococcus pneumoniae; and “SaCBM67” denotes that the CBM67 moiety is derived from Streptomyces avermitilis.
[0083] A CBM for use may comprise a plurality or multiple (i.e. two or more) CBMs. Molecules which comprise a plurality of CBMs may be termed “multivalent CBMs”. A multivalent CBM may, for example, comprise two or more CpCBMs, two or more SpCBMs, two or more SaCBMs as described above. A multivalent CBM may comprise a mixture of different CBMs, for example one or more CpCBM(s) with one or more Sp/SaCBM(s).
[0084] Multivalent CBM molecules, (for example, a molecule comprising two or more CpCBM32 moieties) may be prepared as constructs comprising multiple CBMs linked by amino acid/peptide linkers. Each CBM may be linked to another by, for example, peptides comprising 5, 10 or 15 amino acids. By way of example, any one or more of the following peptides may be used to link two or more CBMs to produce a multivalent CBM:
[0085]
| (i) 5 amino acid linkers: | |
| (SEQ ID NO: 9) | |
| ALNGS | |
| (SEQ ID NO: 10) | |
| LQALG | |
| (SEQ ID NO: 11) | |
| GGNSG | |
| (SEQ ID NO: 12) | |
| GGGSG | |
| (SEQ ID NO: 13) | |
| GGSLG | |
| (SEQ ID NO: 14) | |
| GGGSA | |
| (ii) 10 amino acid linkers: | |
| (SEQ ID NO: 15) | |
| ALNGSGGGSG | |
| (SEQ ID NO: 16) | |
| LQALGGGGSL | |
| (iii) | |
| 15 amino acid linkers: | |
| (SEQ ID NO: 17) | |
| ALNGSGGGSGGGGSG |
[0086] Thus, the various aspects and embodiments of this disclosure (uses, CBMs for use, methods and medicaments) may exploit molecules which comprise, consist of or consist essentially of CBMs selected from the group consisting of:
-
- [0087] (i) one or more CpCBM32(s);
- [0088] (ii) one or more SpCBM47(s);
- [0089] (iii) one or more SaCBM67(s); and
- [0090] (iv) one or more SpCBM70(s).
[0091] The molecules for use may further comprise an oligomerisation domain. Suitable oligomerisation domains may exhibit an ability to self-associate to form multimer structures, for example, trimers. An oligomerisation domain for use may comprise any molecule with the above-mentioned oligomerisation properties or any functional fragment thereof. For example, one or more (for example two) CBM molecules may be bound, coupled or fused to an oligomerisation domain—the resulting CBM molecule::oligomerisation domain “fusion” may then be used (with one or more other such “fusions”) as a molecule for modulating cell growth and/or activity and/or for treating or preventing any of the diseases and/or conditions disclosed herein.
[0092] Suitable oligomerisation domains may be derived from, for example, Pseudomonas aeruginosa pseudaminidase. An exemplary Pseudomonas aeruginosa pseudaminidase sequence amino acid sequence has been deposited under accession number PA0579 and is reproduced below as SEQ ID NO: 18 (438 amino acids).
[0093]
| MNTYFDIPHR LVGKALYESY YDHFGQMDIL | |
| SDGSLYLIYR RATEHVGGSD GRVVFSKLEG | |
| GIWSAPTIVA QAGGQDFRDV AGGTMPSGRI | |
| VAASTVYETG EVKVYVSDDS GVTWVHKFTL | |
| ARGGADYNFA HGKSFQVGAR YVIPLYAATG | |
| VNYELKWLES SDGGETWGEG STIYSGNTPY | |
| NETSYLPVGD GVILAVARVG SGAGGALRQF | |
| ISLDDGGTWT DQGNVTAQNG DSTDILVAPS | |
| LSYIYSEGGT PHVVLLYTNR TTHFCYYRTI | |
| LLAKAVAGSS GWTERVPVYS APAASGYTSQ | |
| VVLGGRRILG NLFRETSSTT SGAYQFEVYL | |
| GGVPDFESDW FSVSSNSLYT LSHGLQRSPR | |
| RVVVEFARSS SPSTWNIVMP SYFNDGGHKG | |
| SGAQVEVGSL NIRLGTGAAV WGTGYFGGID | |
| NSATTRFATG YYRVRAWI |
[0094] The oligomerisation domain of SEQ ID NO: 18 is from amino acid residue 333 to 438 (grey highlight)—this sequence may be SEQ ID NO: 19.
[0095] Thus an oligomerisation domain for use may comprise from about residue 250, 275, 300, 310, 320, 333, 340 to 350 (i.e. from about residue 250 to about residue 350 including from about any residue therebetween) to about residue 400, 410, 420, 430 or 438 (i.e. to about any residue from about residue 400 residue 438 including to about any residue therebetween) of the P. aeruginosa pseudaminidase trimerisation domain (PaTD) provided by SEQ ID NO: 18. For example, a useful molecule may exploit an oligomerisation domain comprising residues 333 to 438 of SEQ ID NO: 18.
[0096] Further molecules for use in the various aspects and embodiments of this disclosure are described below.
[0097] One molecule for use is designated “Cp2CBM32TD”—this construct comprises a Cp2CBM32 unit which itself comprises 2 CBM32 molecules (shown in bold) derived from Clostridium perfringens, where the 2 copies of CBM32 are linked in tandem by a short peptide linker molecule (dashed underlined). The construct further comprises a trimerisation domain (TD: underlined) which is itself fused to one of the two CBM32s via another short linker moiety (bold underlined). The sequence of an exemplary Cp2CBM32TD is provided below as SEQ ID NO: 20.
[0098]
| SEQ ID NO: 20 | |
| GAMAIIETAIPQSEMTASATSEEGQDPASSAIDG | |
| NTNTMWHTKWNGSDALPQSLSVNLGSSRKVSSIA | |
| ITPRTSGNNGFITKYEIHAINNGVETLVAEGTWE | |
| ENNLVKTVTFDSPIDAEEIKITAIQGVGGFASIA | |
| ELNVYEGGGSGAIIETAIPQSEMTASATSEEGQD | |
| PASSAIDGNTNTMWHTKWNGSDALPQSLSVNLGS | |
| SRKVSSIAITPRTSGNNGFITKYEIHAINNGVET | |
| LVAEGTWEENNLVKTVTFDSPIDAEEIKITAIQG | |
VGGFASIAELNVYE VPDFESDWFSVSSNS | |
| LYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPS | |
| YFNDGGHKGSGAQVEVGSLNIRLGTGAAVWGTGY | |
| FGGIDNSATTRFATGYYRVRAWI |
[0099] One molecule for use is designated “Sp2CBM47TD”—this construct a Sp2CBM47 unit which itself comprises 2 CBM47 molecules (shown in bold) derived from Streptococcus pneumoniae, where the 2 copies of CBM47 are linked in tandem by a short peptide linker molecule (dashed underlined). The construct further comprises a trimerisation domain (TD: underlined) which is itself fused to one of the two CBM47s via another short linker moiety (bold underlined). The sequence of an exemplary Sp2CBM47TD is provided below as SEQ ID NO: 21.
[0100]
| SEQ ID NO: 21 | |
| GAMGTPDKFNDGNLNIAYAKPTTQSSVDYNGDPN | |
| RAVDGNRNGNFNSGSVTHTRADNPSWWEVDLKKM | |
| DKVGLVKIYNRTDAETQRLSNFDVILYDNNRNEV | |
| AKKHVNNLSGESVSLDFKEKGARYIKVKLLTSGV | |
PLSLAEVEVFRES TPDKFNDGNLNIAYAK | |
| PTTQSSVDYNGDPNRAVDGNRNGNFNSGSVTHTR | |
| ADNPSWWEVDLKKMDKVGLVKIYNRTDAETQRLS | |
| NFDVILYDNNRNEVAKKHVNNLSGESVSLDFKEK | |
| GARYIKVKLLTSGVPLSLAEVEVFRESGGSLGVP | |
| DFESDWFSVSSNSLYTLSHGLQRSPRRVVVEFAR | |
| SSSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNI | |
| RLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRA | |
| WI |
[0101] One molecule for use is designated “Sa2CBM67TD”—this construct comprises a Sa2CBM67 unit which itself comprises 2 CBM67 molecules (grey highlight) derived from Streptococcus avermitilis, where the 2 copies of CBM67 are linked in tandem by a short peptide linker molecule (dashed underlined). The construct further comprises a trimerisation domain (TD: underlined) which is itself fused to one of the two CBM67s via another short linker moiety (bold underlined). The sequence of an exemplary Sa2CBM67TD is provided below as SEQ ID NO: 22.
[0102]
| SEQ ID NO: 22 | |
| GAMAPSLEGSSWIWFPEGEPANSAPAATRWFRRT | |
| VDLPDDITGATLAISADNVYAVSVDGAEVARTDL | |
| EADNEGWRRPAVIDVLDHVHSGNNTLAVSASNAS | |
| VGPAGWICVLVLTTASGEKKIFSDASWKSTDHEP | |
| ADGWREPDFDDSGWPAAKVAAAWGAGPWGRVA | |
 APSLEGSSWIWFPEGEPANSAPAATRWF | |
| RRTVDLPDDITGATLAISADNVYAVSVDGAEVAR | |
| TDLEADNEGWRRPAVIDVLDHVHSGNNTLAVSAS | |
| NASVGPAGWICVLVLTTASGEKKIFSDASWKSTD | |
| HEPADGWREPDFDDSGWPAAKVAAAWGAGPWGRV | |
| AGGSLGVPDFESDWFSVSSNSLYTLSHGLQRSPR | |
| RVVVEFARSSSPSTWNIVMPSYFNDGGHKGSGAQ | |
| VEVGSLNIRLGTGAAVWGTGYFGGIDNSATTRFA | |
| TGYYRVRAWI |
[0103] One molecule for use is designated “Sp2CBM70TD”—this construct comprises a Sp2CBM70 unit which itself comprises 2 CBM70 molecules (shown in bold) derived from Streptococcus pneumoniae, where the 2 copies of CBM70 are linked in tandem by a short peptide linker molecule (dashed underlined). The construct further comprises a trimerisation domain (TD: underlined) which is itself fused to one of the two CBM70s via another short linker moiety (bold underlined). The sequence of an exemplary Sp2CBM70TD is provided below as SEQ ID NO: 23.
[0104]
| SEQ ID NO: 23 | |
| GAMENLVENGDFGQTEDGSSPWTGSKAQGWSAWV | |
| DQKNSADASTRVIEAKDGAITISSHEKLRAALHR | |
| MVPIEAKKKYKLRFKIKTDNKIGIAKVRIIEESG | |
| KDKRLWNSATTSGTKDWQTIEADYSPTLDVDKIK | |
LELFYETGTGTVSFKDIELVEVADQLS NL | |
| VENGDFGQTEDGSSPWTGSKAQGWSAWVDQKNSA | |
| DASTRVIEAKDGAITISSHEKLRAALHRMVPIEA | |
| KKKYKLRFKIKTDNKIGIAKVRIIEESGKDKRLW | |
| NSATTSGTKDWQTIEADYSPTLDVDKIKLELFYE | |
| TGTGTVSFKDIELVEVADQLSGGSLGVPDFESDW | |
| FSVSSNSLYTLSHGLQRSPRRVVVEFARSSSPST | |
| WNIVMPSYFNDGGHKGSGAQVEVGSLNIRLGTGA | |
| AVWGTGYFGGIDNSATTRFATGYYRVRAWI |
[0105] In a first aspect, the various molecules disclosed herein may be for use in therapy. Further, the various molecules disclosed herein may be for use as medicaments. In the context of this aspect, the reader should understand that the “molecules disclosed herein” at least include the following:
-
- [0106] (i) molecules comprising one or more CBM32(s);
- [0107] (ii) molecules comprising one or more CBM47(s);
- [0108] (iii) molecules comprising one or more CBM67(s);
- [0109] (iv) molecules comprising one or more CBM70(s);
- [0110] (v) molecules comprising Cp2CBM32TD;
- [0111] (vi) molecules comprising Sp2CBM47TD;
- [0112] (vii) molecules comprising Sa2CBM67TD; and
- [0113] (viii) molecules comprising Sp2CBM70TD;
[0114] In one aspect, there is provided a molecule comprising a CBM32 for use in a method of modulating cell growth and/or cell activity. The molecule comprising CBM32 may comprise or be Cp2CBM32TD.
[0115] In another aspect, there is provided a molecule comprising a CBM47 for use in a method of modulating cell growth and/or cell activity. The molecule comprising CBM47 may comprise or be Sp2CBM47TD.
[0116] In a further aspect, there is provided a molecule comprising a CBM67 for use in a method of modulating cell growth and/or cell activity. The molecule comprising CBM67 may comprise or be Sa2CBM67TD.
[0117] Additionally, there is provided a molecule comprising a CBM70 for use in a method of modulating cell growth and/or cell activity. The molecule comprising CBM70 may comprise or be Sp2CBM70TD.
[0118] Another aspect, provides a method of modulating cell growth and/or activity, said method comprising contacting a cell with a molecule comprising CBM32. The method may be an in vitro method. The molecule comprising CBM32 may comprise or be Cp2CBM32TD.
[0119] An additional aspect provides a method of modulating cell growth and/or activity, said method comprising contacting a cell with a molecule comprising CBM47. The method may be an in vitro method. The molecule comprising CBM47 may comprise or be Sp2CBM47TD.
[0120] A further aspect provides a method of modulating cell growth and/or activity, said method comprising contacting a cell with a molecule comprising CBM67. The method may be an in vitro method. The molecule comprising CBM67 may comprise or be Sa2CBM67TD.
[0121] Another aspect provides a method of modulating cell growth and/or activity, said method comprising contacting a cell with a molecule comprising CBM70. The method may be an in vitro method. The molecule comprising CBM70 may comprise or be Sp2CBM70TD.
[0122] As stated, a “molecule comprising a CBM32”, a “molecule comprising a CBM47”, a “molecule comprising a CBM67” and/or a “molecule comprising a CBM70”—may consist essentially of the respective CBM32, CBM47, CBM67 or CBM70 or may consist of the respective CBM32, CBM47, CBM67 or CBM70.
[0123] The CBM32, CBM47, CBM67 or CBM70 component of a molecule referred to in the above aspects may comprise the complete wild-type CBM32, CBM47, CBM67 or CBM70 sequences (as provided by each of SEQ ID NOS: 1-8 above). Additionally, or alternatively, the various aspects of this disclosure may exploit a carbohydrate binding fragment of any of the CBM32, 47, 67 or 70 sequences disclosed herein (including the sequences of SEQ ID NOS: 1-8).
[0124] It should be noted that the term CBM32, CBM47, CBM67 or CBM70 further embraces recombinant molecules generated from reference CBM32, CBM47, CBM67 or CBM70 sequences (including SEQ ID NOS: 1-8). Again, these recombinant molecules can comprise full length CBM32, CBM47, CBM67 or CBM70 sequences or carbohydrate binding fragments thereof.
[0125] For convenience, the term CBM32/47/67/70 will be used to refer to all of the above described CBM molecules (which molecules comprise, consist essentially of, or consist of one or more CBM32(s), one or more CBM47(s), one or more CBM67(s) or one or more CBM70(s) or carbohydrate binding fragments of any of these.
[0126] The term “modulating” may embrace any increase or decrease in one or more aspects of cell growth and/or activity. In other words, a molecule described herein (for example, a molecule comprising one or more CBM32/47/67/70(s)) may either inhibit certain aspects of cell growth and/or activity or may induce or stimulate other aspects of cell growth and/or activity.
[0127] The terms “growth” and “activity” as applied to cells may embrace processes and/or phenomena associated with one or more of cell proliferation, cell viability, cell migration, cell metabolism, cell differentiation and/or cell morphology/phenotype. The terms “growth” and/or “activity” may further include the response of a cell to certain exogenous and/or endogenous factors or stimuli including, for example, responses to certain compounds of the immune system, cytokines, chemokines and one or more environmental factors (light, temperature, pressure, mechanical stress and the like). Thus, the CBM32/47/67/70 molecules disclosed herein may be used to modulate (inhibit, decrease or increase) levels of cell responsiveness.
[0128] Given that CBM32/47/67/70 have been shown to modulate cell growth and activity (as described above), it will be appreciated that these molecules may be put to a number of related medical and veterinary applications and uses.
[0129] For example, a molecule comprising one or more CBM32/47/67/70(s) may be applied to the treatment and/or prevention of a disease or condition in which aberrant cell growth, and/or aberrant cell activity is a factor.
[0130] Disclosed herein is a molecule comprising a CBM32/47/67/70 for use in treating and/or preventing a disease and/or condition caused, contributed to and/or characterised by aberrant cell growth and/or activity. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0131] (i) a molecule comprising one or more CpCBM32(s);
- [0132] (ii) a molecule comprising one or more SpCBM47(s);
- [0133] (iii) a molecule comprising one or more SaCBM67(s);
- [0134] (iv) a molecule comprising one or more SpCBM70(s);
- [0135] (v) a molecule comprising Cp2CBM32TD;
- [0136] (vi) a molecule comprising Sp2CBM47TD;
- [0137] (vii) a molecule comprising Sa2CBM67TD; and
- [0138] (viii) a molecule comprising Sp2CBM70TD.
[0139] Further, disclosed is the use of a molecule comprising a CBM32/47/67/70 for the manufacture of a medicament for the treatment and/or prevention of a disease and/or condition caused, contributed to and/or characterised by aberrant cell growth and/or activity.
[0140] The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0141] (i) a molecule comprising one or more CpCBM32(s);
- [0142] (ii) a molecule comprising one or more SpCBM47(s);
- [0143] (iii) a molecule comprising one or more SaCBM67(s);
- [0144] (iv) a molecule comprising one or more SpCBM70(s);
- [0145] (v) a molecule comprising Cp2CBM32TD;
- [0146] (vi) a molecule comprising Sp2CBM47TD;
- [0147] (vii) a molecule comprising Sa2CBM67TD; and
- [0148] (viii) a molecule comprising Sp2CBM70TD.
[0149] The disclosure also provides a method of treating and/or preventing a disease and/or condition caused, contributed to and/or characterised by aberrant cell growth and/or activity, said method comprising the step of administering a therapeutically effective amount of a molecule comprising a CBM32/47/67/70 to a subject in need thereof. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0150] (i) a molecule comprising one or more CpCBM32(s);
- [0151] (ii) a molecule comprising one or more SpCBM47(s);
- [0152] (iii) a molecule comprising one or more SaCBM67(s);
- [0153] (iv) a molecule comprising one or more SpCBM70(s);
- [0154] (v) a molecule comprising Cp2CBM32TD;
- [0155] (vi) a molecule comprising Sp2CBM47TD;
- [0156] (vii) a molecule comprising Sa2CBM67TD; and
- [0157] (viii) a molecule comprising Sp2CBM70TD.
[0158] Diseases which are caused, contributed to or characterised by aberrant cell growth and/or activity may include, for example cell proliferation disorders including, those referred to or classified as benign or malignant conditions. For example, the term “cell proliferation disorders” may include those diseases and/or conditions collectively referred to as “cancer”. The term “cancer” may include, but is not limited to, those cancers referred to as forms of breast cancer, colon cancer, lung cancer, ovarian cancer, glioma and melanoma. In particular, the term cancer (or cell proliferation disorder) may relate to colon cancer, lung cancer and ovarian cancer.
[0159] The term “cancer” may also include those diseases and/or conditions collectively referred to as “leukaemia” (both chronic and acute) and any cancer affecting a mucosal/mucosal associated surface or tissue.
[0160] As such, a molecule comprising a CBM32/47/67/70 described herein may find application in the treatment and/or prevention of cancer. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0161] (i) a molecule comprising one or more CpCBM32(s);
- [0162] (ii) a molecule comprising one or more SpCBM47(s);
- [0163] (iii) a molecule comprising one or more SaCBM67(s);
- [0164] (iv) a molecule comprising one or more SpCBM70(s);
- [0165] (v) a molecule comprising Cp2CBM32TD;
- [0166] (vi) a molecule comprising Sp2CBM47TD;
- [0167] (vii) a molecule comprising Sa2CBM67TD; and
- [0168] (viii) a molecule comprising Sp2CBM70TD.
[0169] Thus, there is provided a molecule comprising a CBM32/47/67/70 for use in treating and/or preventing cancer. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0170] (i) a molecule comprising one or more CpCBM32(s);
- [0171] (ii) a molecule comprising one or more SpCBM47(s);
- [0172] (iii) a molecule comprising one or more SaCBM67(s);
- [0173] (iv) a molecule comprising one or more SpCBM70(s);
- [0174] (v) a molecule comprising Cp2CBM32TD;
- [0175] (vi) a molecule comprising Sp2CBM47TD;
- [0176] (vii) a molecule comprising Sa2CBM67TD; and
- [0177] (viii) a molecule comprising Sp2CBM70TD.
[0178] Additionally, there is provided use of a molecule comprising a CBM32/47/67/70 for the manufacture of a medicament for the treatment and/or prevention of cancer. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0179] (i) a molecule comprising one or more CpCBM32(s);
- [0180] (ii) a molecule comprising one or more SpCBM47(s);
- [0181] (iii) a molecule comprising one or more SaCBM67(s);
- [0182] (iv) a molecule comprising one or more SpCBM70(s);
- [0183] (v) a molecule comprising Cp2CBM32TD;
- [0184] (vi) a molecule comprising Sp2CBM47TD;
- [0185] (vii) a molecule comprising Sa2CBM67TD; and
- [0186] (viii) a molecule comprising Sp2CBM70TD.
[0187] Also provided is a method of treating and/or preventing cancer, said method comprising the step of administering a therapeutically effective amount of a molecule comprising a CBM32/47/67/70 to a subject in need thereof. The molecule comprising a CBM32/47/67/70 may be selected from the group consisting of:
-
- [0188] (i) a molecule comprising one or more CpCBM32(s);
- [0189] (ii) a molecule comprising one or more SpCBM47(s);
- [0190] (iii) a molecule comprising one or more SaCBM67(s);
- [0191] (iv) a molecule comprising one or more SpCBM70(s);
- [0192] (v) a molecule comprising Cp2CBM32TD;
- [0193] (vi) a molecule comprising Sp2CBM47TD;
- [0194] (vii) a molecule comprising Sa2CBM67TD; and
- [0195] (viii) a molecule comprising Sp2CBM70TD.
[0196] In addition to the general finding that molecules comprising a CBM32/47/67/70 may be useful in the treatment and/or prevention of cancer, molecules comprising one or more CBM32(s) may find particular application in the treatment and/or prevention of a number of specific cancers.
[0197] Accordingly, the disclosure further provides a molecule comprising one or more CBM32(s) for use in the treatment and/or prevention of a cancer selected from the group consisting of:
-
- [0198] (a) ovarian cancer;
- [0199] (b) lung cancer;
- [0200] (c) colon cancer; and
- [0201] (d) breast cancer.
[0202] In view of the above, the disclosure provides:
-
- [0203] (i) a molecule comprising one or more CBM32(s) for use in treating and/or preventing a cancer;
- [0204] (ii) the use of a molecule comprising one or more CBM32(s) in the manufacture of a medicament for the treatment and/or prevention of a cancer; and
- [0205] (iii) a method of treating and/or preventing a cancer by administering a therapeutically effective amount of a molecule comprising one or more CBM32(s) to a subject in need thereof, wherein for each of (i), (ii) and (iii) the cancer is one or more selected from the group consisting of:
- [0206] (a) ovarian cancer;
- [0207] (b) lung cancer;
- [0208] (c) colon cancer; and
- [0209] (d) breast cancer.
[0210] In other words, in addition to being useful in the treatment and/or prevention of each of these individual cancers, each of the CBM32s disclosed herein may find use in the treatment and/or prevention of two, three or all four of the cancers (a) to (d).
[0211] Suitable CBM32s for use in treating and/or preventing any one, two, three or all four of the cancers (a) to (d) may include any of those CBM32s disclosed herein. By way of example only, in some cases, the molecule for use in such methods may be selected from the group consisting of:
-
- [0212] (i) a molecule comprising one, two or more CBM32(s);
- [0213] (ii) a molecule comprising one, two or more CpCBM32(s);
- [0214] (iii) a molecule comprising one, two or more peptides comprising a sequence of SEQ ID NO: 1, 2, or a carbohydrate binding portion thereof; and
- [0215] (iv) a molecule comprising CpCBM32TD.
[0216] Whilst the inventors have identified that CBM32s have general efficacy against a wide range of cancers, in some instances, a molecule comprising one or more CBM32(s) may not demonstrate the same level of efficacy against certain specific cancer types. Thus, in relation to a molecule comprising one or more CBM32(s), the treatment and/or prevention of cancer may exclude the treatment of one or more cancers selected from melanoma, pancreatic cancer and glioma.
[0217] The disclosure further provides a molecule comprising a CBM32 and/or a CBM40 for use in treating and/or preventing a refractory (or resistant) cancer.
[0218] In addition to the CBM32s already described herein, an exemplary CBM40 for use may comprise the sialic acid binding domain of Vibrio cholerae NanH sialidase (VcCBM: a CBM40) and/or the equivalent (or homologous) domain from Streptococcus pneumoniae NanA sialidase (SpCBM: also a CBM40). Of course, similar or homologous sialic acid binding modules present in other organisms are to be encompassed within the scope of the terms “CBM” and “CBM40”. An exemplary Vibrio cholerae NanH sialidase amino acid sequence is deposited under accession number A5F7A4 and is reproduced below as SEQ ID NO: 23 (781 amino acids).
[0219]
| MRFKNVKKTA LMLAMFGMAT SSNAALFDYN | |
| ATGDTEFDSP AKQGWMQDNT NNGSGVLTNA | |
| DGMPAWLVQG IGGRAQWTYS LSTNQHAQAS | |
| SFGWRMTTEM KVLSGGMITN YYANGTQRVL | |
| PIISLDSSGN LVVEFEGQTG RTVLATGTAA | |
| TEYHKFELVF LPGSNPSASF YFDGKLIRDN | |
| IQPTASKQNM IVWGNGSSNT DGVAAYRDIK | |
| FEIQGDVIFR GPDRIPSIVA SSVTPGVVTA | |
| FAEKRVGGGD PGALSNTNDI ITRTSRDGGI | |
| TWDTELNLTE QINVSDEFDF SDPRPIYDPS | |
| SNTVLVSYAR WPTDAAQNGD RIKPWMPNGI | |
| FYSVYDVASG NWQAPIDVTD QVKERSFQIA | |
| GWGGSELYRR NTSLNSQQDW QSNAKIRIVD | |
| GAANQIQVAD GSRKYVVTLS IDESGGLVAN | |
| LNGVSAPIIL QSEHAKVHSF HDYELQYSAL | |
| NHTTTLFVDG QQITTWAGEV SQENNIQFGN | |
| ADAQIDGRLH VQKIVLTQQG HNLVEFDAFY | |
| LAQQTPEVEK DLEKLGWTKI KTGNTMSLYG | |
| NASVNPGPGH GITLTRQQNI SGSQNGRLIY | |
| PAIVLDRFFL NVMSIYSDDG GSNWQTGSTL | |
| PIPFRWKSSS ILETLEPSEA DMVELQNGDL | |
| LLTARLDFNQ IVNGVNYSPR QQFLSKDGGI | |
| TWSLLEANNA NVFSNISTGT VDASITRFEQ | |
| SDGSHFLLFT NPQGNPAGTN GRQNLGLWFS | |
| FDEGVTWKGP IQLVNGASAY SDIYQLDSEN | |
| AIVIVETDNS NMRILRMPIT LLKQKLTLSQ | |
| N |
[0220] The CBM region of SEQ ID NO: 24 is from amino acid residue 25 to 216—this sequence may be SEQ ID NO: 25.
[0221] An exemplary Streptococcus pneumoniae NanA sialidase amino acid sequence has been deposited under accession number P62575 and is reproduced below as SEQ ID NO: 26 (1035 amino acids).
[0222]
| MSYFRNRDID IERNSMNRSV QERKCRYSIR | |
| KLSVGAVSMI VGAVVFGTSP VLAQEGASEQ | |
| PLANETQLSG ESSTLTDTEK SQPSSETELS | |
| GNKQEQERKD KQEEKIPRDY YARDLENVET | |
| VIEKEDVETN ASNGQRVDLS SELDKLKKLE | |
| NATVHMEFKP DAKAPAFYNL FSVSSATKKD | |
| EYFTMAVYNN TATLEGRGSD GKQFYNNYND | |
| APLKVKPGQW NSVTFTVEKP TAELPKGRVR | |
| LYVNGVLSRT SLRSGNFIKD MPDVTHVQIG | |
| ATKRANNTVW GSNLQIRNLT VYNRALTPEE | |
| VQKRSQLFKR SDLEKKLPEG AALTEKTDIF | |
| ESGRNGKPNK DGIKSYRIPA LLKTDKGTLI | |
| AGADERRLHS SDWGDIGMVI RRSEDNGKTW | |
| GDRVTITNLR DNPKASDPSI GSPVNIDMVL | |
| VQDPETKRIF SIYDMFPEGK GIFGMSSQKE | |
| EAYKKIDGKT YQILYREGEK GAYTIRENGT | |
| VYTPDGKATD YRVVVDPVKP AYSDKGDLYK | |
| GNQLLGNIYF TTNKTSPFRI AKDSYLWMSY | |
| SDDDGKTWSA PQDITPMVKA DWMKFLGVGP | |
| GTGIVLRNGP HKGRILIPVY TTNNVSHLNG | |
| SQSSRIIYSD DHGKTWHAGE AVNDNRQVDG | |
| QKIHSSTMNN RRAQNTESTV VQLNNGDVKL | |
| FMRGLTGDLQ VATSKDGGVT WEKDIKRYPQ | |
| VKDVYVQMSA IHTMHEGKEY IILSNAGGPK | |
| RENGMVHLAR VEENGELTWL KHNPIQKGEF | |
| AYNSLQELGN GEYGILYEHT EKGQNAYTLS | |
| FRKFNWDFLS KDLISPTEAK VKRTREMGKG | |
| VIGLEFDSEV LVNKAPTLQL ANGKTARFMT | |
| QYDTKTLLFT VDSEDMGQKV TGLAEGAIES | |
| MHNLPVSVAG TKLSNGMNGS EAAVHEVPEY | |
| TGPLGTSGEE PAPTVEKPEY TGPLGTSGEE | |
| PAPTVEKPEY TGPLGTAGEE AAPTVEKPEF | |
| TGGVNGTEPA VHEIAEYKGS DSLVTLTTKE | |
| DYTYKAPLAQ QALPETGNKE SDLLASLGLT | |
| AFFLGLFTLG KKREQ |
[0223] The CBM region of SEQ ID NO: 26 is from amino acid residue 121 to 305—this sequence may be SEQ ID NO: 27.
[0224] Thus, molecules for use in the treatment of refractory cancer may comprise a protein or peptide having the sequence of SEQ ID NO: 24 or 25 or a sialic acid binding fragment thereof. For example, a useful sialic acid binding molecule may comprise a proteinaceous moiety encoded by the sialic acid binding domain of the nanH gene (encoding sialidase) of V. cholerae (as provided by SEQ ID NO: 24) or an equivalent or homologous gene present in another organism (for example, the equivalent/homologous nanA sialidase gene of S. pneumoniae: see SEQ ID NO: 26). A CBM40 for use in the treatment of refractory cancer may comprise from about residue 1, 5, 10, 15, 25 or 30 (i.e. from 1-30 or from any amino acid residue there between) to about residue 150, 175, 200, 210, 216, 220-781 (to any residue from 150 to 781 including any residue therebetween) of the V. cholerae sialidase molecule of SEQ ID NOS: 24 or 25. For example, a CBM40 for use in the treatment of refractory cancer may comprise a peptide having a sequence corresponding to residue 25 to about residue 216 of SEQ ID NO: 24 above.
[0225] A further suitable CBM40 for use in the treatment of refractory cancer may comprise a protein or peptide having the sequence of SEQ ID NO: 26 or 27 or a sialic acid binding fragment thereof. For example, a useful may comprise a proteinaceous moiety encoded by the sialic acid binding domain of the Streptococcus pneumoniae nanA gene (encoding sialidase). A CBM40 for use in the treatment of cancer may comprise from about residue 80, 90, 100, 110, 120, 121 to 130 (i.e. from any of about residues 80 to 130 including any residue therebetween) to about residue 250, 275, 300, 305, 310, 320-1035 (i.e. to any residue from about 250-1035 including to about any residue therebetween) of the S. pneumoniae sialidase molecule of SEQ ID NOS: 26 or 27. For example, a CBM40 for use may comprise a peptide having a sequence corresponding to residue 121 to about residue 305 of SEQ ID NO: 26 above.
[0226] One of skill will appreciate that useful CBM40s may comprise sequences which exhibit some degree (for example, 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65% or 60%) sequence identity or homology with the CBM40 sequences of SEQ ID NOS: 24, 25, 26 and 27. All such variant or divergent sequences are to be embraced within the scope of this disclosure and by the term “CBM40”. Identical and/or homologous CBM40 sequences may have carbohydrate binding function.
[0227] A molecule for use in the treatment of refractory cancer may comprise one or more CBM40s. A molecule may comprise a single or individual CBM40—for example, a single VcCBM40 or a single SpCBM40. Alternatively, a molecule for use may comprise a plurality or multiple (i.e. two or more) CBM40s. Molecules which comprise a plurality of CBMs may be termed “multivalent” molecules or CBMs. A multivalent CBM may, for example, comprise two or more VcCBM40s or two or more SpCBM40s. A multivalent CBM may comprise a mixture of different CBMs, for example, one or more VcCBMs with one or more SpCBMs.
[0228] The molecule comprising a CBM32 and/or a CBM40 for use in the treatment of refractory (or resistant) cancer may be selected from the group consisting of:
-
- [0229] (i) a molecule comprising one or more CpCBM32(s);
- [0230] (ii) a molecule comprising Cp2CBM32TD;
- [0231] (iii) a molecule comprising Vc2CBM40TD; and
- [0232] (iv) a molecule comprising Sp2CBM40TD.
[0233] Additionally, the disclosure provides the use of a molecule comprising a CBM32 and/or CBM40 for the manufacture of a medicament for the treatment of a refractory (or resistant) cancer. The molecule comprising a CBM32 and/or CBM40 may be selected from the group consisting of:
-
- [0234] (i) a molecule comprising one or more CpCBM32(s);
- [0235] (ii) a molecule comprising Cp2CBM32TD;
- [0236] (iii) a molecule comprising Vc2CBM40TD; and
- [0237] (iv) a molecule comprising Sp2CBM40TD.
[0238] Also disclosed is a method of treating a refractory (or resistant) cancer, said method comprising administering a subject in need thereof a therapeutically effective amount of a molecule comprising a CBM32 and/or CBM40. The molecule comprising a CBM32 and/or CBM40 may be selected from the group consisting of:
-
- [0239] (i) a molecule comprising one or more CpCBM32(s);
- [0240] (ii) a molecule comprising Cp2CBM32TD;
- [0241] (iii) a molecule comprising Vc2CBM40TD; and
- [0242] (iv) a molecule comprising Sp2CBM40TD.
[0243] A subject in need thereof or indeed a subject to be administered a molecule disclosed herein or a medicament comprising the same, may be any subject suffering (or suspected as suffering) from (i) a cell proliferation disorder, (ii) cancer, (iii) any other disease and/or condition described herein; (iv) a disease or condition caused, contributed to or characterised by aberrant cell growth and/or activity; (v) one or more cancers selected from the group consisting of (a) breast cancer, (b) colon cancer, (c) lung cancer, (d) ovarian cancer, (e) glioma and (f) melanoma; (vi) one or more cancers selected from the group consisting of (a) lung cancer, (b) colon cancer and (c) ovarian cancer; and/or (v) a refractory (or resistant) cancer.
[0244] Additionally, or alternatively, any subject may be a subject predisposed or susceptible to (i) a cell proliferation disorder, (ii) cancer, (iii) any other disease and/or condition described herein; (iv) a disease or condition caused, contributed to or characterised by aberrant cell growth and/or activity; (v) one or more cancers selected from the group consisting of: (a) breast cancer; (b) colon cancer; (c) lung cancer; (d) ovarian cancer; (e) glioma and (f) melanoma; or (vi) one or more cancers selected from the group consisting of (a) lung cancer, (b) colon cancer; and (c) ovarian cancer.
[0245] Refractory or resistant cancers may include cancers that do not respond to first line or preferred medicaments (including standard or preferred chemotherapeutic or radiotherapeutic options). Refractory or resistant cancers may include those cancers that are resistant to (or do not respond to) cisplatin. The term refractory cancer or resistant cancer may embrace refractory or resistant ovarian cancer. The terms refractory (ovarian) cancer and resistant (ovarian) cancer may include ovarian cancers that are resistant to cisplatin.
[0246] Accordingly, the disclosure provides (i) a molecule comprising one or more CpCBM32(s); (ii) a molecule comprising Cp2CBM32TD; (iii) a molecule comprising Vc2CBM40TD; and/or (iv) a molecule comprising Sp2CBM40TD, for use in the treatment of refractory (or resistant) ovarian cancer.
[0247] It should be understood that any of the treatments described herein, may involve the use of one or more molecules of this disclosure to treat, ameliorate or reduce, one or more symptoms of the various diseases and disorders described herein. By way of example, the symptoms of a disease such as cancer may include, for example, the presence of tumours and/or cell masses. As such, the molecules described herein may be used to modulate (for example stop, retard, inhibit or reduce) tumour formation and/or the metastasis thereof. The molecules may also be used to reduce the overall size of a tumour. Certain tumours, including those that are large and/or aggressive, are often easier to surgically remove if they have first been reduced in size. Typically, chemo- and/or radiotherapy-based treatments might be used to reduce the size of a tumour but treatments such as this may be replaced by and/or supplemented with treatments based upon the use of a molecule comprising a CBM32/47/67/70. As stated, molecules comprising a CBM32/47/67/70 exhibit an ability to modulate cell growth and/or activity and therefore, without wishing to be bound by theory, the mechanism underpinning the ability of any one of the disclosed molecules to affect the size of a tumour may be rooted in the cell proliferation, differentiation and/or metabolism modulating effects of the molecule.
[0248] In view of the above, the successful treatment of a tumour may therefore be characterised by a reduction in tumour size, a reduction in an observed or detectable/detected level of tumour metastasis, angiogenesis within tumorigenic tissue and/or tissue invasion.
[0249] A molecule of this disclosure may be for use in methods of modulating (for example inhibiting, restricting or reducing) tumour growth, development and/or metastasis in subjects in need thereof. The molecules described herein may be formulated as compositions for use in modulating tumour growth, development and/or metastasis or used in the manufacture of medicaments for achieving the same. This disclosure also provides a molecule comprising a CBM32/47/67/70 for use in treating a tumour. Further, described is the use of a molecule comprising a CBM32/47/67/70 for the manufacture of a medicament for treating a tumour. Also, the disclosure provides a method of treating a tumour, said method comprising administering a molecule comprising a CBM32/47/67/70 to a subject (or tumorigenic tissue) in need thereof.
[0250] As defined earlier, the term “a subject in need thereof” may embrace any subject suspected as having a tumour or diagnosed with a tumour and/or subjects that are identified as being predisposed and/or susceptible to tumours. The term “tumours” may include refractory or resistant tumours. The term tumours may include refractory or resistant ovarian cancer tumours.
[0251] The present disclosure therefore provides various applications for molecules comprising a CBM32/47/67/70 and which have been identified as modulators of cell growth and/or activity. Any given molecule (comprising a CBM32/47/67/70) may be identified as a modulator of cell growth and/or activity via the various experiments and assays described in the examples section of this patent application. For example, the cell wound scratch assay is one example of an assay that may be adapted to determine whether any given “test” molecule exhibits the necessary ability to modulate cell growth, cell migration and/or activity. Additionally, or alternatively, a BrdU cell proliferation assay may be used to determine any effect of a test agent (for example, a molecule comprising a CBM32/47/67/70) on cell proliferation, growth and/or activity. Briefly, cells may be cultured in a medium supplemented with BrdU—as cells grow and proliferate, the BrdU is incorporated into de novo-synthesized DNA as a substitute for thymidine. This labels progeny cells and the amount of BrdU incorporation can be used as a measure or indicator of cell proliferation/growth. BrdU detection may be achieved by the use of antibodies with specificity or affinity for BrdU.
[0252] In other cases, a metabolic-based assay, such as a CellTiter-Glo® 2.0 Assay (CTG®2.0) may be used to determine any effect of a test agent (for example, a molecule comprising a CBM32/47/67/70) on cell proliferation, growth and/or activity. In such assays, an amount of ATP (adenosine triphosphate) may be assessed to determine a number of metabolically active cells (and so may provide a measure of viable cells). The number of viable cells following treatment with a test agent may be used as a measure or indicator of cell proliferation/growth.
[0253] Alternatively or additionally, a DNA-staining based assay such as a CyQUANT® Direct Cell Proliferation Assay may be used to determine any effect of a test agent (for example, a molecule comprising a CBM32/47/67/70) on cell proliferation, growth and/or activity. In such assays, the number of viable cells may be determined using a DNA stain, e.g. a cell-permeant DNA-binding dye. Again, the number of viable cells following treatment with a test agent may be used as a measure or indicator of cell proliferation/growth.
[0254] Thus, the disclosure could relate to those molecules which, via a cell activity modulation assay (for example, a cell wound scratch assay), exhibit an ability to modulate cell growth and/or activity. To this end, the disclosure further provides a method of identifying molecules (including molecules comprising a CBM32/47/67/70) for use in methods of modulating cell growth and/or activity or for the various medical and/or veterinary applications described herein, said method comprising subjecting a test compound to an assay capable of reporting an effect of the test compound on cell growth and/or activity, wherein the test compound is a molecule comprising a CBM32/47/67/70 and if the assay reports that the compound has an effect on any aspect of cell growth and/or activity, the compound may be useful in the treatment and/or prevention of diseases and/or conditions of the type described herein. The assay which is capable of reporting an effect of the test compound on cell growth and/or activity may be a cell wound scratch assay, BrdU type, a CellTiter-Glo® 2.0 type and/or a CyQUANT® Direct Cell Proliferation assay as described herein.
[0255] Molecules which comprise a CBM32/47/67/70, may find further application as molecules which may be conjugated, bound or joined to or associated with, other entities for the purpose of targeting or delivering that entity to some tissue or cell.
[0256] Molecules of this type may be otherwise known as “therapeutic warheads” or “conjugates”. Without wishing to be bound by theory, the presence of ligands for the various CBMs which may be comprised within the molecules of this disclosure (for example CBM32, CBM47, CBM67 and/or CBM70) in certain cell receptors and membrane bound molecules, may allow the various molecules described herein to be exploited as a means to deliver conjugated heterologous molecules (that is, a molecule distinct from and different to the molecule comprising a CBM32/47/67/70) to said cells or tissues comprising said cells. Such, conjugated molecules may be useful in the treatment of cancer, where the molecules described herein (which molecules exhibit affinity for carbohydrates expressed on the surface of cells) may be used to direct therapeutic and/or cytotoxic moieties thereto.
[0257] By way of example, a molecule as described herein (including any of the CBM32/47/67/70 molecules) may be conjugated to one or more (for example, two, three, four or more) moieties which are, for example, therapeutic and/or cytotoxic. Thus, the disclosure relates to CBM32/47/67/70 molecule conjugates.
[0258] CBM32/47/67/70 molecule conjugates may comprise a CBM32/47/67/70 molecule of this disclosure conjugated (joined, bound or otherwise associated with) to a heterologous moiety. The heterologous moiety may comprise a therapeutic and/or cytotoxic moiety which may be conjugated to some part of the CBM32/47/67/70 molecule.
[0259] For example, the heterologous moiety may be conjugated to one or both ends of the CBM32/47/67/70 molecule. The heterologous moiety may be additionally or alternately conjugated (or even fused) to an internal portion of the CBM32/47/67/70 molecule. It will be appreciated that however the heterologous moiety is to be conjugated to the CBM32/47/67/70 molecule, the molecule (nor its conjugation) should not (substantially) interfere with or ablate or reduce the carbohydrate binding property of the CBM32/47/67/70 molecule.
[0260] As stated, the heterologous moiety may be a drug useful in the treatment of a disease which affects a cell or tissue expressing a receptor which comprises the ligand for any one of the CBM32, CBM47, CBM67 or CBM70 molecules. For example, the drug may be a chemotherapeutic drug for use in the treatment of cancer and the like. The heterologous moiety may be a cytotoxic moiety capable of killing or inducing apoptosis in, a cell. The heterologous moiety may comprise a molecule which is able to recruit specific cells to or into a particular tissue. For example, the heterologous moiety may be, for example, a T cell receptor (TCR) which may be used as a means to recruit T cells to, for example a tumour or cancerous tissue.
[0261] The present disclosure may provide compositions for use in the various uses, medicaments and methods described herein. As such, any of the molecules comprising a CBM32/47/67/70 described herein may be formulated for use.
[0262] For convenience, and with reference to the section below describing compositions, formulations and the like, it should be noted that both molecules comprising a CBM32/47/67/10 as described herein and any conjugates comprising the same (for example, CBM32/47/67/70::drug conjugates/fusions) shall be included under the general term “molecule comprising a CBM32/47/67/70”.
[0263] A molecule comprising a CBM32/47/67/70 may be formulated for use and as a therapeutic or pharmaceutical composition. The various compositions may comprise one or more of the molecules described herein and any given treatment may require the administration (together, concurrently or separately) of one or more of these compositions. It should be noted that a composition according to this disclosure may further comprise one or more other therapeutic moieties—for example, molecules, small molecules, antibodies, oligonucleotides and the like useful in the treatment of one or more diseases and/or conditions. Additionally, or alternatively, a molecule comprising a CBM32/47/67/70 may be administered together with one or more other (different) therapeutic entities—wherein the one or more other (different) therapeutic entities may be used for the treatment of the same or a different disease. The term “administered together” embraces administration of a CBM32/47/67/70 before, after and/or at the same time as the administration of the one or more other therapeutic entities.
[0264] The molecules described herein may be formulated for enteral (including oral), parenteral and/or topical administration and one of skill will appreciate that the precise formulation may vary depending on the route of administration.
[0265] Pharmaceutical compositions according to the present invention may be prepared conventionally, comprising substances that are customarily used in pharmaceuticals and as described in, for example, Remington's The Sciences and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press 2012) and/or Handbook of Pharmaceutical Excipients, 7th edition (compiled by Rowe et al, Pharmaceutical Press, 2012)—the entire content of all of these documents and references being incorporated by reference.
[0266] A therapeutic or pharmaceutical composition of this disclosure (that is a composition comprising a molecule comprising a CBM32/47/67/70 and for use in any of the medicaments or methods described herein—including the methods of or medicaments for, modulating cell growth and/or activity and/or treating cancer) may be formulated together with one or more pharmaceutically acceptable excipients, carriers, adjuvants and buffers. The compositions can be administered, e.g. orally (including mucosally), parentally, intraperitoneally, enterally, intramuscularly, subcutaneously, intravenously or via any other routes useful to achieve the desired effect (in this case effects which include, modulation of cell growth/activity, treatment or prevention of diseases/conditions associated with the same and/or cancer and/or modulation of tumour growth). As stated, depending on the chosen route of administration, the exact composition of the formulation may vary.
[0267] A therapeutic or pharmaceutical formulation comprising a molecule comprising a CBM32/47/67/70 and for administration to a subject may be coated, encapsulated or enveloped in a material which protects the molecule from the action of enzymes, acids and other natural compounds/conditions (including, for example, compounds (including antibodies), cells and processes of the immune system) which may inactivate or denature the compound and/or its carbohydrate binding properties.
[0268] Among the various standard and conventional excipients that may be available for use in compositions comprising the molecules described herein, are those pharmaceutically acceptable organic or inorganic carrier substances which are suitable for parenteral, enteral, oral (including mucosal) and other routes of administration that do not deleteriously react with the molecule(s) comprising a CBM32/47/67/70.
[0269] Where molecules comprising a CBM32/47/67/70 are to be formulated for parental administration, the compositions may be sterile.
[0270] The composition may comprise an oil-based or aqueous solution, a suspension and/or an emulsion.
[0271] In other embodiments, the composition may take the form of an implant, such as for example a (dissolvable or biodegradable) film, pessary or implant (including suppositories).
[0272] The pharmaceutical preparations comprising the molecules described herein may be mixed with stabilizers, wetting agents, emulsifiers, salts (for use in influencing osmotic pressure), buffers and/or other substances that do not react deleteriously with the active compounds.
[0273] One or more of the molecules described herein may be formulated for and administered, orally. As stated, oral administration would include mucosal administration which would itself would include administration intranasally and/or by inhalation.
[0274] Compositions for use may include solid dosage forms which are suitable for oral administration. These may include, for example capsules, tablets, pills, powders, and granules. In any given solid dosage form, a molecule comprising a CBM32/47/67/70 (or any conjugate comprising the same) may be admixed with at least one inert pharmaceutically-acceptable excipient. Examples of suitable excipients will be known to one of skill in this field but may include, for example fillers or extenders, humectants, wetting agents, binders, disintegrating agents, solution retarders, absorption accelerators, adsorbents, lubricants or mixtures thereof. A tablet, pill or capsule may further comprise a buffering agent. Solid dosage forms such as tablets, dragees, capsules, pills and/or granules also can be prepared with coatings and shells, such as coatings which protect against the gastrointestinal environment and/or stomach acid.
[0275] A solid dosage form may contain opacifying agents and can also be formulated so as to ensure the delayed release of the active agent (in this case a molecule comprising a CBM32/47/67/70 or a conjugate comprising the same) in or to a specific part of the intestinal tract.
[0276] Solid compositions for oral administration can be formulated in a unit dosage form, each dosage containing an appropriate dose of a molecule comprising a CBM32/47/67/70 (or conjugate comprising the same). The exact amount of a molecule comprising a CBM32/47/67/70 (or conjugate comprising the same) contained within any given solid dosage form will vary depending on the intended use. A solid composition may contain a “unit dose”—a unit dose containing a quantity of a molecule comprising a CBM32/47/67/70 (or conjugate containing the same) calculated to produce the desired effect (for example modulation of cell growth and/or activity) over the course of a treatment period.
[0277] Liquid dosage forms for oral administration may (as stated) include emulsions, solutions, suspensions, syrups, and elixirs. In addition to the compound or composition, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers.
[0278] Any of the disclosed molecules may be used in any suitable amount. As stated, the acid molecules may be formulated for oral, mucosal or parenteral administration and as such, the precise formulation may depend on the intended route of administration. The amount of a molecule comprising a CBM32/47/67/70 present in any given dose may be in the region of 0.1 μg-1000 μg. For example, amounts of about 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 1 μg, 10 μg, 20 μg, 25 μg, 50 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg or 900 μg. The selected amount of the CBM32/47/67/70 molecule may be formulated in a specific volume of a pharmaceutically acceptable excipient, diluent and/or buffer. The volume of excipient, diluent or buffer may be about 10 μL to 5 mL. For example, the required amount of CBM32/47/67/70 molecule may be combined (or formulated) with about 15 μL, 20 μL, 25 μL, 30 μL, 35 μL, 40 μL, 45 μL, 50 μL, 55 μL, 60 μL, 65 μL, 70 μL, 75 μL, 80 μL, 85 μL, 90 μL, 95 μL, 100 μL, 200 μL, 250 μL, 300 μL, 400 μL, 500 μL, 600 μL, 700 μL, 800 μL, 900 μL, 1 mL, 2 mL, 3 mL or 4 mL. For example, 100 μg CBM32/47/67/70 molecule may be combined with about 250 μL of excipient to yield a final concentration of 400 μg/mL. Doses at concentrations of about 0.1 μg/mL-1 mg/mL may be used including, for example, doses at 5 μg/mL, 10 μg/mL, 20 μg/mL, 25 μg/mL, 50 μg/mL, 100 μg/mL, 200 μg/mL, 300 μg/mL, 500 μg/mL, 600 μg/mL, 700 μg/mL, 800 μg/mL or 900 μg/mL.
[0279] In use, a dose of a CBM32/47/67/70 molecule, administered as part of the treatment and/or prevention of a cell proliferation and/or differentiation disorder (for example, cancer), may be administered multiple times over a number of days, weeks months or years. For example, after an initial (or first) administration, a dose of a CBM32/47/67/70 molecule may be administered again at about (+/−1 or 2 days) 3, 4, 5, 6, 7, 17, 21, 28 and/or 35 days later. On any given day, a specific dose of a CBM32/47/67/70 molecule may be administered 1, 2, 3 or more times. Each time, the CBM32/47/67/70 molecule may be administered (by whatever route is considered best to affect a suitable treatment or to induce prophylaxis against the development of a cell proliferation and/or differentiation disorder.
Detailed Description
[0280] The present invention will now be described in detail by reference to the following Figures which show:
[0281] FIG. 1 : Proliferation data (BrdU incorporation assay). Different cancer cell lines (Melanoma ((a), A2058), Breast ((b), MDA.MB.231), Pancreatic ((c), PANC1) and Lung ((d), A549) were treated with Cp2CBM32TD (400 μg/mL), PBS (control), sialic acid binding CBM40 agents (Sp2CBMTD (400 μg/mL), Vc2CBMTD (400 μg/mL) or Vc4CBM (400 μg/mL)) or sialic acid binding null CBM40 mutant (Sp2(R274Q)CBMTD (400 μg/mL)) and left for 24 hours. The cells were then incubated with BrdU for 2-6 hrs. An ELISA assay was performed to measure the quantity of BrdU incorporated into the DNA. This assay is a standard assay to measure cell growth/proliferation. A two-way ANOVA was used to show statistical significance vs the control group (p of <0.0001 represented by ****, p of <0.001 represented by ***, p of <0.01 represented by ** and p of <0.1 represented by *)
[0282] FIG. 2 : Proliferation data (BrdU incorporation assay). Different cancer cell lines ((a), Glioma (T98G), Colon ((b), SW620) and Ovarian ((c), PE014)) were treated with Cp2CBM32TD (400 μg/mL), PBS (control), sialic acid binding CBM40 agents (Sp2CBMTD (400 μg/mL), Vc2CBMTD (400 μg/mL) or Vc4CBM (400 μg/mL)) or sialic acid binding null CBM40 mutant (Sp2(R274Q)CBMTD (400 μg/mL)) and left for 24 hours. The cells were then subject to a BrdU assay and incubated for 2-6 hrs. An ELISA assay was performed to measure the quantity of BrdU incorporated into the DNA. This assay is a standard assay to measure cell growth/proliferation. A two-way ANOVA was used to show statistical significance vs the control group (p of <0.0001 represented by ****, p of <0.001 represented by ***, p of <0.01 represented by ** and p of <0.1 represented by *).
[0283] FIG. 3 : Percentage inhibition of cell proliferation in human-derived metastatic ovarian cancer cell lines PE01, PE01 cisplatin-resistant (PE01-CR) and PE014. (a) using Cp2CBM32TD (GalNAc/galactose/lactose binding CBM from Clostridium perfringens) against three ovarian cell lines, including a cisplatin-resistant form (PE01-CR). (b) using Vc2CBMTD against three ovarian cell lines (PE01, PE01-CR, PE014). (c) using Sp2CBMTD against three ovarian cell lines (PE01, PE01-CR, PE014).
[0284] FIG. 4 : Proliferation data (BrdU incorporation assay). Different cancer cell lines (Melanoma ((a), A2058), Breast ((b), MDA.MB.231), Pancreatic ((c), PANC1) and Lung ((d), A549) were treated with 2CBM47TD (400 μg/mL), 2CBM67TD (400 μg/mL), 2CBM70TD (400 μg/mL), PBS (control) or sialic acid binding CBM40 agent Sp2CBMTD (400 μg/mL) and left for 24 hours. The cells were then incubated with BrdU for 2-6 hrs. An ELISA assay was performed to measure the quantity of BrdU incorporated into the DNA. This assay is a standard assay to measure cell growth/proliferation. A two-way ANOVA was used to show statistical significance vs the control group (p of <0.0001 represented by ****, p of <0.001 represented by ***, p of <0.01 represented by ** and p of <0.1 represented by *).
[0285] FIG. 5 : Proliferation data (BrdU incorporation assay). Different cancer cell lines ((a), Glioma (T98G), Colon ((b), SW620) and Ovarian ((c), PE014, (d) PE01)) were treated with 2CBM47TD (400 μg/mL), 2CBM67TD (400 μg/mL), 2CBM70TD (400 μg/mL), PBS (control) or sialic acid binding CBM40 agent Sp2CBMTD (400 μg/mL) and left for 24 hours. The cells were then subject to a BrdU assay and incubated for 2-6 hrs. An ELISA assay was performed to measure the quantity of BrdU incorporated into the DNA. This assay is a standard assay to measure cell growth/proliferation. A two-way ANOVA was used to show statistical significance vs the control group (p of <0.0001 represented by ****, p of <0.001 represented by ***, p of <0.01 represented by ** and p of <0.1 represented by *).
[0286] FIG. 6 : Proliferation data (BrdU incorporation assay). Ovarian cancer cell (PE01 cisplatin resistant (CR)) was treated with Sp2CBMTD (400 μg/mL), 2CBM47TD (400 μg/mL), 2CBM67TD (400 μg/mL), 2CBM70TD (400 μg/mL) or PBS (control) and left for 24 hours. The cells were then subject to a BrdU assay and incubated for 2-6 hrs. An ELISA assay was performed to measure the quantity of BrdU incorporated into the DNA. This assay is a standard assay to measure cell growth/proliferation. A two-way ANOVA was used to show statistical significance vs the control group (p of <0.0001 represented by ****, p of <0.001 represented by ***, p of <0.01 represented by ** and p of <0.1 represented by *).
[0287] FIG. 7 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Ovarian cancer cell line (SK-OV-3) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0288] FIG. 8 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Ovarian cancer cell line (TOV-21G) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0289] FIG. 9 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Colorectal cancer cell line (Gp2D) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0290] FIG. 10 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Breast cancer cell line (MDA-MB-231) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0291] FIG. 11 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Breast cancer cell line (CAMA-1) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0292] FIG. 12 : Proliferation data obtained from (a) CellTiter Glo® 2.0 Assay (CTG2.0); and (b) CyQUANT® Direct Cell Proliferation Assay. Lung cancer cell line (NCI-H441) was treated with Cp2CBM32TD and left for 72 hours as outlined below. A dose response curve was generated with nine different concentrations using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
Experimental
Part A
[0293] A number of different cancer cell lines were treated with various CBM test agents, each comprising one or more molecules comprising a CBM selected from the group consisting of CBM32, CBM40, CBM47, CBM67 and CBM70.
[0294] These test agents were assessed in the BrdU cell proliferation assays as outlined above under each of FIGS. 1 to 6 .
[0295] The results of these assays are shown in FIGS. 1 to 6 .
Part B
[0296] The CBM Cp2CBM32TD was selected for further investigation using the following assays:
-
- [0297] (i) CellTiter Glo® 2.0 Assay (CTG2.0); and
- [0298] (ii) CyQUANT® Direct Cell Proliferation Assay.
[0299] The CellTiter-Glo® 2.0 Assay provides a homogeneous method to determine the number of viable cells in culture by quantitating the amount of ATP present, which indicates the presence of metabolically active cells. The CyQUANT® Direct Cell Proliferation Assay relies on the use of a cell-permeant DNA-binding dye in combination with a background suppression reagent. These procedures are fully described in the Promega CellTiter-Glo® 2.0 Assay Technical Manual TM403 (October 2018) and the CyQUANT® Direct Cell Proliferation Assay Molecular Probes manual MP 35011 (20 Jul. 2009).
[0300] Cell lines that have been preserved in liquid nitrogen are thawed and expanded in growth media. Once cells have reached expected doubling times, screening begins. 25 μL of cells in growth media are seeded in black 384-well tissue culture treated plates at 500-1500 cells per well. Assay plates were equilibrated via centrifugation and incubated for 24 hours at 37° C. prior to compound treatment. At the time of treatment, a set of timepoint 0 (To) assay plates (which do not receive treatment) are collected and readings for DNA-content and viability measured using CyQUANT® Direct (ThermoFisher) Cell Proliferation Assay and CellTitre-Glo® 2.0 (Promega) metabolic-based assay, respectively. 15 μL/well of assay reagents are added to assay plates. Nine different concentrations were assessed using a 3-fold dilution series from 3 mg/mL to 0.457 μg/mL.
[0301] Timepoint 0 (To) plates are either read for fluorescence (CyQUANT®) or absorbance (CellTitre-Glo® 2.0) on Envision plate readers (Perkin Elmer). Assay plates are incubated with compound for 72 hours and are then analysed using CyQUANT® Direct Cell Proliferation Assay and CellTitre-Glo® 2.0 metabolic-based assay.
[0302] Growth Inhibition (GI) was used as a measure of cell growth. The GI percentages are calculated by applying the following test and equation:
[0303]
where T is the signal measure for a test article, V is the untreated/vehicle-treated control measure, and Vo is the untreated/vehicle control measure at time zero (also colloquially referred as T0 plates). This formula is derived from the Growth Inhibition calculation used in the National Cancer Institute's NCI-60 high throughput screen.
where T is the signal measure for a test article, V is the untreated/vehicle-treated control measure, and Vo is the untreated/vehicle control measure at time zero (also colloquially referred as T0 plates). This formula is derived from the Growth Inhibition calculation used in the National Cancer Institute's NCI-60 high throughput screen.
[0304] A GI reading of 0% represents no growth inhibition and would occur in instances where the T reading at 72 hours is comparable to the V reading at the respective time period. A GI of 100% represents complete growth inhibition (cytostasis) and in this case cells treated with compound for 72 hours would have the same endpoint reading as T0 control cells. A GI of 200% represents complete death (cytotoxicity) of all cells in the culture well and in this case the T reading at 72 hours will be lower than the T0 control.
[0305] Inhibition was also provided as a measure of cell viability. Inhibition levels of 0% represent no inhibition of cell growth by treatment. Inhibition of 100% represents no doubling of cell numbers during the treatment window. Both cytostatic and cytotoxic treatments can yield an Inhibition percentage of 100%. Inhibition percentage is calculated using the following formula:
[0306]
where T is the treated and U is the untreated/vehicle control.
where T is the treated and U is the untreated/vehicle control.
[0307] In each case, cells were seeded in growth media in black 384-well tissue culture treated plates and equilibrated via centrifugation. The treated assay plates were incubated with the test compound for 72 hours. After treatment, the plates were developed for endpoint analysis using either the CellTiter-Glo® 2.0 Assay or the CyQUANT® Direct Cell Proliferation Assay.
[0308] The results are shown in FIGS. 7 to 12 .
[0309] During these further investigations, the inventors identified that Cp2CBM32TD did show anti-proliferative activity against the breast cancer cell line MDA.MB.231 (see FIGS. 10a and 10b ) and also the breast cancer cell line CAMA-1 (see FIGS. 11a and 11b ). This same level of activity against MDA.MB.231 cancer cells was not observed in the BrdU assay.
[0310] Without being bound by theory, the inventors hypothesize that this difference may be attributable to the population doubling time of MDA.MB.231 cells (which is approximately 36 hrs). Therefore, it is believed that the shorter treatment period in the BrdU assay (which had a duration of 24 hours) was not sufficient to properly demonstrate the anti-proliferative activity of Cp2CBM32TD against MDA.MB.231 cells.
Claims
The invention claimed is:
1. A method for the treatment of cancer, the method comprising administering a carbohydrate binding module to a subject in need thereof, wherein the carbohydrate binding module is a carbohydrate binding module of carbohydrate binding module Family 32 (CBM32).
2. The method of claim 1, wherein the carbohydrate binding module of carbohydrate binding module Family 32 (CBM32) comprises SEQ ID NO: 1 or SEQ ID NO: 2 or a carbohydrate binding portion thereof.
3. The method of claim 1, wherein the cancer is selected from the group consisting of:
(a) ovarian cancer;
(b) lung cancer;
(c) colon cancer; and
(d) breast cancer.
4. The method according to claim 1, wherein the carbohydrate binding module comprises a single CpCBM32, or two or more CBMs selected from the group consisting of:
(i) a CBM32; and
(ii) a CpCBM32.
5. The method according to claim 1, wherein the carbohydrate binding module comprises Cp2CBM32TD.
6. The method of claim 1, wherein the carbohydrate binding module is selected from the group consisting of:
(i) a molecule comprising two or more CBM32 (s);
(ii) a molecule comprising one, two or more CpCBM32 (s);
(iii) a molecule comprising one, two or more peptide(s) or protein(s) comprising a sequence of SEQ ID NO: 1, 2, or a carbohydrate binding portion thereof, and
(iv) a molecule comprising Cp2CBM32TD.
7. The method of claim 6, wherein the cancer is selected from the group consisting of:
(a) ovarian cancer;
(b) lung cancer;
(c) colon cancer; and
(d) breast cancer.
8. A method of treating a refractory cancer, the method comprising administering to a subject in need thereof a carbohydrate binding module classified as a CBM32 or a molecule comprising a carbohydrate binding module classified as a CBM32.
9. The method according to claim 8, wherein the refractory cancer is refractory ovarian cancer.
Patent Citations (3)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| JP5917913(B2) | 2016-05-01 | Applicant | |
| WO2018055373(A1) | 2018-03-01 | Applicant | |
| WO2019138222(A1) | 2019-07-01 | Applicant |
Non-Patent Literature (18)
- H. Connaris et al, “Prevention of influenza by targeting host receptors using engineered proteins”, Proceedings of the National Academy of Sciences, vol. {0} 111, No. {0} 17, Apr. 29, 2014 (Apr. 29, 2014) (Year: 2014).Examiner
- Evans et al. Q. J. Med 1999: 92: 299-307 (Year: 1999).Examiner
- Komenaka et al., Clinics in Dermatology, 2004, vol. 22, p. 251-265 (Year: 2004).Examiner
- Schiffman et al., The New England Journal of Medicine, vol. 353, No. 20, p. 2101-2104, 2005 (Year: 2005).Examiner
- Tseng et al. Enzyme and Microbial Technology 41 (2007) 5-12 (Year: 2007).Examiner
- Hernandez-Ledesma et al. Peptides, vol. 30, p. 426-430, 2009 (Year: 2009).Examiner
- Park et al. Gut Liver 2013;7(6):629-641 (Year: 2013).Examiner
- Li et al. Toxins 2016, 8(11), 341-355 (Year: 2016).Examiner
- Riberio et al. Biochem J (2016) 473 (14): 2109-2118. (Year: 2016).Examiner
- Sokolenko et al. Frontiers in molecular biosciences. Aug. 27, 2018;5:76. (Year: 2018).Examiner
- Cuzick et al. The Lancet, vol. 361, p. 296-300, 2003. (Year: 2003).Examiner
- UniProt entry A0A2X2YJF2: nanJ sequence; URL: https://www.uniprot.org/uniprotkb/A0A2X2YJF2/entry (Year: 2018) (Year: 2018).Examiner
- International Search Report and Written Opinion corresponding to PCT/GB2020/050170 (16 pages).Applicant
- Ficko-Blean, Elizabeth , et al., “N-Acetylglucosamine Recognition by a Family 32 Carbohydrate-Binding Module from Clostridium perfringens NagH”, Journal of Molecular Biology 390(2), 2009, 208-220.Applicant
- Guillen, Daniel , et al., “Carbohydrate-binding domains: multiplicity of biological roles”, Applied Microbiology and Biotechnology 85, 2010, 1241-1249.Applicant
- Shimizu, Tohru , et al., “Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater”, PNAS 99(2), 2002, 996-1001.Applicant
- Accession No. WP_003450115 “exo-alpha-sialidase [Clostridium perfringens]” NCBI (2 pages) (May 25, 2013).Applicant
- Accession No. A0A2X2YJF2 “Exo-alpha-sialidase [Clostridium perfringens]” UniProtKB; accessed Dec. 2023 (4 pages).Applicant